Search Results for “brca” - Page 10 - Ovarian Cancer Research Alliance

Study Finds Genetic Testing Underutilized Among Ovarian Cancer Patients

...While the numbers of those tested increased over time, and especially accelerated after the approval of PARP inhibitors for BRCA1 and BRCA2 mutated chemotherapy-refractory ovarian cancer in December 2014, the...

June 2016 ASCO Highlights

...intravenous chemotherapy and stating that BRCA1/2 patients could benefit from the use of IP. All agreed that there are unresolved issues regarding the use of IP chemotherapy and much work...

New Genetic Markers for Ovarian Cancer Discovered

...were identified for breast (n = 1) and ovarian (n = 2) cancers in BRCA1 mutation carriers and for breast cancer (n = 1) in BRCA2 mutation carriers. An epigenetic...

Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

...114, and 172) resulted in longer PFS using intraperitoneal compared to intravenous chemotherapy and stating that BRCA1/2 patients could benefit from the use of IP. All agreed that there are...

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

...regardless of BRCA mutation status. Niraparib was first approved by the FDA for treatment of recurrent ovarian cancer in 2017. This most recent approval means ovarian cancer patients do not...

Press Release: Cancer Groups Praise Coverage of Genetic Counseling and Testing Under Affordable Care Act, Urge Coverage of Other Vital Services

...and ovarian cancer risk in women with a family history of cancer. Breast and ovarian cancers have been linked to mutations in the BRCA1 and BRCA2 genes. The Ovarian Cancer...

Why I Give: Continuing the Rivkin Center Legacy with Ovarian Cancer Research Alliance

...tested negative for BRCA1 and BRCA2 mutations —inherited genetic mutations that are known to elevate risk—but Kim knows there is more to discover. That’s part of the research we need:...

Press Release: Nearly Half of Women With Ovarian Cancer Are Not Receiving Critical Genetic Testing

...particularly in identifying BRCA mutations and other genetic markers that guide treatment with precision therapies such as PARP inhibitors. Key findings of the OCRA analysis show that only 52% of...

OCRFA Research Finds New Genetic Variants Linked to Ovarian Cancer

A study published in Nature Genetics has identified nine new susceptibility loci, or disease-associated alleles, for different epithelial ovarian cancer (EOC) histotypes and three susceptibility loci within BRCA1 and 2...

What’s New in Ovarian Cancer Research and Treatment

...for ovarian cancer continues to show promise. The SOLO-1 trial, for instance, illustrates that the PARP inhibitor olaparib can significantly improve progression-free survival for patients with an inherited BRCA mutation....

Need to talk?

Free Genetic Testing Program

Harnessing AI for Early Detection

We Need Your Voice

Become a Monthly Donor

OCRA Joins Forces with Rivkin Center

Suggested Links

Quick Links

Suggested Links

Quick Links

Search Results for: "brca"

Search Again

Study Finds Genetic Testing Underutilized Among Ovarian Cancer Patients

June 2016 ASCO Highlights

New Genetic Markers for Ovarian Cancer Discovered

Highlights from the June 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Niraparib Receives FDA Approval as First-Line Maintenance Therapy for Advanced Ovarian Cancer

Press Release: Cancer Groups Praise Coverage of Genetic Counseling and Testing Under Affordable Care Act, Urge Coverage of Other Vital Services

Why I Give: Continuing the Rivkin Center Legacy with Ovarian Cancer Research Alliance

Press Release: Nearly Half of Women With Ovarian Cancer Are Not Receiving Critical Genetic Testing

OCRFA Research Finds New Genetic Variants Linked to Ovarian Cancer

What’s New in Ovarian Cancer Research and Treatment

Stay Informed

Quick Links

About